🇺🇸 Atovaquone / Proguanil in United States

1,529 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 1,529

Most-reported reactions

1. Nausea — 203 reports (13.28%)
2. Vomiting — 188 reports (12.3%)
3. Pneumonia — 171 reports (11.18%)
4. Cholelithiasis — 164 reports (10.73%)
5. Schizophrenia — 163 reports (10.66%)
6. Condition Aggravated — 138 reports (9.03%)
7. Hypomania — 127 reports (8.31%)
8. Blood Bilirubin Increased — 126 reports (8.24%)
9. Hepatic Enzyme Increased — 125 reports (8.18%)
10. Hepatotoxicity — 124 reports (8.11%)

Source database →

Frequently asked questions

Is Atovaquone / Proguanil approved in United States?

Atovaquone / Proguanil does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Atovaquone / Proguanil in United States?

Radboud University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.